Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
Wave Life Sciences Ltd. - Ordinary Shares (WVE)
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.wavelifesciences.com/news-releases?page=1%2c0%2c0%2c0
Company Research
Source: GlobeNewswire
This press release corrects and replaces the company’s press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under “WVE-007 (GalNAc-siRNA)” – “Next steps.” Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe and well tolerated to date Activin E reduction in lowest dose cohort of INLIGHT was sustained through 6 months, supporting once or twice a year dosing Multiple clinical data updates from INLIGHT, including body composition and body weight, are anticipated starting in 4Q 2025 Additional updates included announcement of WVE-008, PNPLA3 RNA editing candidate for liver disease, with CTA submission anticipated in 2026 Preclinical data supports Wave’s emerging pipeline of hepatic and extra-hepatic RNA editing and siRNA programs; emerging modality adds capability
Show less
Read more
Impact Snapshot
Event Time:
WVE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WVE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WVE alerts
High impacting Wave Life Sciences Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
WVE
News
- Wave Life Sciences: Being Realistic, There Is Still So Much To Prove [Seeking Alpha]Seeking Alpha
- Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead [Seeking Alpha]Seeking Alpha
- Jefferies Maintains “Buy” Rating on Wave Life Sciences (WVE) Amid Its Improving Competitive Positioning [Yahoo! Finance]Yahoo! Finance
- WAVE Life Sciences Ltd (WVE) Q3 2025 Earnings Call Highlights: Promising Clinical Advances and ... [Yahoo! Finance]Yahoo! Finance
- WAVE Life Sciences (NASDAQ:WVE) had its price target raised by analysts at Wedbush from $18.00 to $20.00. They now have an "outperform" rating on the stock.MarketBeat
WVE
Earnings
- 11/10/25 - Miss
WVE
Sec Filings
- 11/17/25 - Form 8-K
- 11/14/25 - Form 4
- 11/14/25 - Form 4
- WVE's page on the SEC website